Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2028-06-30

Summary

Minorities have higher rates of diabetes, poorer glucose control, and higher complications and mortality rates than white people. Several recently approved diabetes medicines improve cardiovascular and renal outcomes through two different mechanisms. This study will explore key determinants of blood glucose levels namely beta cell function after short-term randomized, parallel group treatment with FDA approved Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA), or FDA approved Sodium-Glucose co-Transporter-2 Inhibitor (SGLT-2i). Because diabetes in black people shows a unique ability to recover pancreatic insulin secretion, it is important to determine whether the effects of these drug classes differentially improve pancreatic beta cell function.

• Phase: PHASE4

Details

• Lead Sponsor: MaryAnn Banerji
• Collaborator: The New York Community Trust
• Treatments: bexagliflozin; Canagliflozin; dapagliflozin; dulaglutide; empagliflozin; Liraglutide; semaglutide; Sodium-Glucose Transporter 2 Inhibitors